Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
BRIDGEWATER, N.J. - On Tuesday, Amneal Pharmaceuticals (NASDAQ:AMRX) reported second-quarter adjusted earnings that exceeded analyst expectations, driven by strong performance in its Specialty segment, while raising its full-year profit guidance.
The company’s shares rose 1.13% in after hours trading following the announcement.
The generic drugmaker posted adjusted earnings of $0.25 per share for the second quarter, significantly outpacing the analyst consensus of $0.17 and representing a 56% increase from $0.16 in the same period last year. Revenue reached $725 million, up 3% year-over-year, though slightly below analyst expectations of $748.18 million.
Amneal’s Specialty segment was the standout performer with a 23% revenue increase, fueled by strong sales of key branded products including CREXONT, RYTARY, and UNITHROID. Meanwhile, the Affordable Medicines segment showed modest 1% growth, while the AvKARE segment experienced a 4% decline.
"Amneal delivered another quarter of solid growth, strong profitability, and we are pleased to raise our full year 2025 guidance," said Chirag and Chintu Patel, Co-Chief Executive Officers. "The quarter was also marked by strong commercial uptake of CREXONT for Parkinson’s disease, and the FDA approval of Brekiya autoinjector for the acute treatment of migraine and cluster headache in adults."
The company reported adjusted EBITDA of $184 million, a 13% increase compared to the second quarter of 2024, reflecting higher revenue and improved gross margins.
Based on its strong performance, Amneal raised its full-year 2025 guidance, now expecting adjusted earnings per share of $0.70-$0.75, up from the previous range of $0.65-$0.70, and in line with the analyst consensus of $0.71. The company maintained its revenue forecast of $3.0-$3.1 billion.
In a significant financial move, Amneal successfully completed a $2.7 billion debt refinancing on August 1, which the company said will reduce interest costs and extend debt maturities to 2032, providing greater financial flexibility.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.